Treatment of psoriasis and psoriatic arthritis in patients with concomitant chronic, severe viral infections, particularly HIV or HBV, represents a challenge, due to contraindication to conventional immunomodulating systemic drugs and biologics, including anti-TNF alpha, anti-IL12/23, and anti-IL17 agents. Recently, apremilast, a selective inhibitor of phosphodiesterase E4 has been suggested to be a safe and effective therapeutic option in HIV-infected population with psoriatic arthritis. We report the case of a patient with psoriatic arthritis and concomitant HIV and HBV infection successfully treated with apremilast.
Manfreda, V., Esposito, M., Campione, E., Bianchi, L., Giunta, A. (2019). Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections. POSTGRADUATE MEDICINE, 131(3), 239-240 [10.1080/00325481.2019.1575613].
Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections
Campione E.;Bianchi L.;Giunta A.
2019-01-01
Abstract
Treatment of psoriasis and psoriatic arthritis in patients with concomitant chronic, severe viral infections, particularly HIV or HBV, represents a challenge, due to contraindication to conventional immunomodulating systemic drugs and biologics, including anti-TNF alpha, anti-IL12/23, and anti-IL17 agents. Recently, apremilast, a selective inhibitor of phosphodiesterase E4 has been suggested to be a safe and effective therapeutic option in HIV-infected population with psoriatic arthritis. We report the case of a patient with psoriatic arthritis and concomitant HIV and HBV infection successfully treated with apremilast.| File | Dimensione | Formato | |
|---|---|---|---|
|
Apremilast efficacy and safety in a psoriatic.pdf
solo utenti autorizzati
Licenza:
Copyright dell'editore
Dimensione
2.63 MB
Formato
Adobe PDF
|
2.63 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
